SEC Form 4 · accession 0001209191-17-065785
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Srinivas Akkaraju
Director
Period of report
Dec 12, 2017
Accepted (ET)
Dec 14, 2017 · 8:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 12, 2017 | P | 14,774 | $9.40 | A | 735,494 | I | see footnote |
| Common StockF2,F1 | Dec 13, 2017 | P | 68,400 | $8.97 | A | 803,894 | I | see footnote |
| Common StockF3,F1 | Dec 14, 2017 | P | 26,600 | $8.99 | A | 830,494 | I | see footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.
- F2Represents the weighted average purchase price of the Shares purchased ranging from a low of $8.97 to a high of $8.98 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F3Represents the weighted average purchase price of the Shares purchased ranging from a low of $8.98 to a high of $9.00 per share. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.